Source: Eur Respir J 2007; 29: 128-133
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
van Puijenbroek R., Bosquee L., Meert A-P., Schallier D., Goeminne J-C., Tits G., Collard P., Nackaerts K., Canon J-L., Duplaquet F., Galdermans D., Germonpre P., Azerad M-A., Vandenhoven G., De Greve J., Vansteenkiste J.. Gefitinib monotherapy in advanced nonsmall cell lung cancer: a large Western community implementation study. Eur Respir J 2007; 29: 128-133

Member's Comments

No comment yet.

Related content which might interest you: The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer Source: Eur Respir Rev 2010 19: 186-196 Year: 2010 A prospective phase II study of gefitinib for chemo-naïve patients with advanced non-small cell lung cancer with epidermal growth factor receptor gene mutations Source: Annual Congress 2006 - Lung cancer treatment Year: 2006 Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3 Source: Eur Respir J 2011; 39: 172-179 Year: 2012 Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3 Source: Eur Respir J 2012; 39: 172-179 Year: 2012 Customising chemotherapy in advanced nonsmall cell lung cancer: daily practice and perspectives Source: Eur Respir Rev 2011; 20: 45-52 Year: 2011 Nationwide real-world cohort study of first line TKI treatment in epidermal growth factor receptor mutated non-small cell lung cancer. Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology Year: 2020 Chemotherapy in small cell lung cancer Source: ISSN=1025-448x, ISBN=1-904097-18-9, page=234 Year: 2001 Chemotherapy in small cell lung cancer Source: Eur Respir J 2001; 18: 1026-1043 Year: 2001 The results of gefitinib (Iressa) treatment in 89 patients with advanced non-small cell lung cancer (NSCLC) on expanded access programme (EAP) Source: Eur Respir J 2006; 28: Suppl. 50, 753s Year: 2006 Compassionate-use gefitinib in non–small cell lung cancer (NSCLC): results from a US expanded access program (EAP) Source: Eur Respir J 2004; 24: Suppl. 48, 231s Year: 2004 Cost-utility analysis of chemotherapy in symptomatic advanced nonsmall cell lung cancer Source: Eur Respir J 2006; 27: 895-901 Year: 2006 Should there be a specific management for large cell neuroendocrine carcinoma? Source: Annual Congress 2005 - Neuroendocrine tumours of the lung Year: 2005 Lung cancer: does age affect treatment strategy? Source: Eur Respir Mon; 2009: 43:306–326 Year: 2009 Should patients with metastatic NSCLC and poor performance status be treated by chemotherapy? Source: Annual Congress 2007 - Treatment of metastatic nonsmall cell lung cancer in the era of targeted therapies Year: 2007 First-line treatment of EGFR-mutated nonsmall cell lung cancer: critical review on study methodology Source: Eur Respir Rev 2014; 23: 92-105 Year: 2014 Treatment of advanced non-small cell lung cancer Source: Annual Congress 2005 - PG2 - Lung cancer: non-small cell lung cancer treatment Year: 2005 Efficacy of Afatinib, Erlotinib, and Gefitinib on epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) patients with brain metastasis: a network meta-analysis Source: International Congress 2018 – Lung cancer: modern therapies and beyond Year: 2018 Chemotherapy improves low performance status lung cancer patients Source: Eur Respir J 2007; 30: 1186-1192 Year: 2007 The role of palliative radiotherapy in locally advanced non small cell lung cancer Source: Annual Congress 2007 - Therapy of lung cancer Year: 2007 Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation Source: Eur Respir J 2011; 37: 624-631 Year: 2011